Press release - Phost'in

13/01/2025

Press release

Clinical trials, Glioblastoma, I/O, I/O trials, Oncology, PhOx430

Phost’in Therapeutics and the Gianni Bonadonna Foundation Announce Opening of 2 Expansion Cohorts in the PhAST Trial

Montpellier, France – August 2023, 25th

25/08/2023

Press release

Taiho Pharmaceutical and Phost’in Therapeutics announce an Option and License Agreement on the First-in-Class GnT-V inhibitor PhOx430

Montpellier, France – August 2023, 25th

04/07/2023

Press release

FRANCE 2030: Phost’in Therapeutics is awarded 1.7m€ in the I-NOV competition to support clinical trial and industrialization of its First-In-Class GnT-V inhibitor

Montpellier, France – July 2023, 4th

14/09/2022

Press release

Phost’in Therapeutics and the Gianni Bonadonna Foundation announce First Patients Dosed with the First-In-Class PhOx430 in an adaptive Phase I/II in patients with Advanced Solid Tumors

Montpellier, France – Sept 2022, 14th

07/06/2022

Press release

Phost’in Therapeutics announces approval of French and Italian Health Agency for a first European clinical trial application in patients with advanced solid tumors, in collaboration with Foundation Gianni Bonnadona

Montpellier, France – June 2022, 07th

09/03/2022

Press release

Phost’in Therapeutics joins TechShare 2022, Euronext’s paneuropean Pre-IPO training program

Montpellier, France – Mars 2022, 09th

11/09/2020

Press release

Phost’in Therapeutics announces €2.5m funding from Bpifrance to support regulatory and early clinical development of its First-In-Class N-Glycosylation Inhibitor

Montpellier, France – Sept 2020, 11th

17/06/2020

Press release

Phost’in Therapeutics strengthens management with appointment of veteran lifescience executives Dr. Alain Herrera and Pr. Bernard Pau

Montpellier, France – June 2020, 17th

20/04/2020

Press release

Phost’in Therapeutics raises €10.3m to develop First-in-Class N-glycosylation Inhibitors for Cancer Treatment

Montpellier, France – April 2020, 20th